# Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases

> **NCT07301164** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 10 (estimated)

## Conditions studied

- System Lupus Erythematosus
- Systemic Sclerosis (SSc)
- Inflammatory Myositis
- Antiphospholipid Syndrome
- ANCA Associated Vasculitis
- Sjogren Syndrome

## Interventions

- **BIOLOGICAL:** BCT301

## Key facts

- **NCT ID:** NCT07301164
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-11
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07301164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07301164, "Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07301164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*